Baxter International Inc.

Análisis de la acción Baxter International Inc. (BAX)

$24.920

-0.364 (-1.46%)Al cierre

Loading chart…
Máximo
25.250
Apertura
25.200
Precio medio ponderado por volumen
24.99
Volumen
5.49M
Capitalización
17.08B
Mínimo
24.810
Importe
137.21M
EV/EBITDA, TTM
7.73

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others.

www.baxter.com

Análisis de IA of Baxter International Inc. (BAX)

Mantener

Baxter International Inc is currently priced at $25.30, which is below the average analyst price target of $27.75. The company has shown a year-to-date change of +29.74%, indicating strong performance. However, the forward P/E ratio is 11.57, which suggests it may not be undervalued. The main risk is the recent earnings guidance, which has been lowered by some analysts, reflecting uncertainty in future growth.

Métricas de valoración

El PER previsto actual de Baxter International Inc. (BAX) es 11.57, frente a su media de 5 años de 13.80.

PER previsto

Valor razonable
Media 5A P/E
13.80
P/E actual
11.57
Sobrevalorada
17.35
Infravalorada
10.25

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
11.73
EV/EBITDA actual
7.73
Sobrevalorada
14.90
Infravalorada
8.57

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.47
P/S actual
1.10
Sobrevalorada
2.01
Infravalorada
0.94

Escenarios de precio de Alphio AI para BAX

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%BAX

$28.00

Precio del escenario

B

Base

Base · 50%BAX

$25.49

Precio del escenario

B

Bajista

Bajista · 25%BAX

$18.18

Precio del escenario

Ballenas con BAX en cartera

E

Edmond de Rothschild Asset Management (France)

+ Con en carteraBAX

+8.91%

Rentabilidad a 3 meses

R

RWC Partners Limited

+ Con en carteraBAX

+3.32%

Rentabilidad a 3 meses

F

First Pacific Advisors, LP

+ Con en carteraBAX

+2.23%

Rentabilidad a 3 meses

G

Greenhaven Associates Inc

+ Con en carteraBAX

+1.08%

Rentabilidad a 3 meses

T

Tontine Management, LLC

+ Con en carteraBAX

-15.02%

Rentabilidad a 3 meses

Cronología de eventos

2026-10-20 (ET)

12:30:00

U.S. 10-Year Treasury Yield Falls to Near One-Month Lows

2026-08-19 (ET)

08:30:00

Baxter International Appoints John Rogers as CFO

2026-08-04 (ET)

09:00:00

Baxter International Launches Cash Tender Offers Up to $500M

2026-07-30 (ET)

09:00:00

Microsoft's Strong Earnings Boosts Stock Futures Rebound

Noticias

Preguntas frecuentes sobre BAX, respondidas por Alphio AI

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is currently priced at $25.30, which is below the average analyst price target of $27.75. The company has shown a year-to-date change of +29.74%, indicating strong performance. However, the forward P/E ratio is 11.57, which suggests it may not be undervalued. The main risk is the recent earnings guidance, which has been lowered by some analysts, reflecting uncertainty in future growth.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar